Practical recommendations for the use of therapeutic drug monitoring of biopharmaceuticals in inflammatory diseases

Abstract : Biopharmaceuticals directed against tumor necrosis factor-alpha, integrins, interleukins, interferons and their receptors have become key agents for the management of inflammatory diseases in the fields of gastroenterology, rheumatology, dermatology and neurology. However, response to these treatments is far from optimal. Therapeutic failure has been attributed in part to inadequate serum concentrations of the drug and the formation of antidrug antibodies (ADA). Therapeutic drug monitoring (TDM) based on drug concentrations and ADA represents a pharmacologically sound tool for guiding dosage adjustments to optimize exposure. Although becoming standard practice in tertiary care centers, the widespread accessibility and recognition of TDM is hindered by several hurdles, including a lack of education of health care providers on TDM. In this paper, the Monitoring of monoclonal Antibodies Group in Europe (MAGE) provides an introduction on the fundamental principles of the concept of TDM, aiming to educate clinicians and assist them in the process of implementing TDM of anti-inflammatory biopharmaceuticals.
Complete list of metadatas

https://hal-univ-tours.archives-ouvertes.fr/hal-01980768
Contributor : Denis Mulleman <>
Submitted on : Monday, January 14, 2019 - 4:22:14 PM
Last modification on : Thursday, February 21, 2019 - 10:30:03 AM

Links full text

Identifiers

Collections

Citation

Erwin Dreesen, Peter Bossuyt, Denis Mulleman, Ann Gils, Dora Pascual-Salcedo. Practical recommendations for the use of therapeutic drug monitoring of biopharmaceuticals in inflammatory diseases. Clinical Pharmacology: Advances and Applications, 2017, Volume 9, pp.101-111. ⟨10.2147/CPAA.S138414⟩. ⟨hal-01980768⟩

Share

Metrics

Record views

51